S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:SGYP

Synergy Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.01
MA: $0.02
$0.03
52-Week Range N/A
VolumeN/A
Average Volume6.08 million shs
Market Capitalization$7.44 million
P/E RatioN/A
Dividend YieldN/A
Beta4.94
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Read More
Synergy Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.82 million
Book Value($0.02) per share

Profitability

Net Income$-224,330,000.00
Net Margins-332.11%

Miscellaneous

EmployeesN/A
Market Cap$7.44 million
Next Earnings DateN/A
OptionableOptionable

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analyst estimates of $15.65 million.
View Synergy Pharmaceuticals' earnings history
.

Who are some of Synergy Pharmaceuticals' key competitors?

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), Opko Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and SLS International (SLS).

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the following people:
  • Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)
  • Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)
  • Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
  • Ms. Pamela Cebulski, Sr. VP of Marketing
  • Ms. Marianne Jackson, Sr. VP of Sales & Market Access

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

What is Synergy Pharmaceuticals' official website?

The official website for Synergy Pharmaceuticals is www.synergypharma.com.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.